Health Advisory

Please deliver a copy of the accompanying alert to each provider in your organization.

Thank you

Questions regarding this alert may be directed to the office of:

Alan Melnick, MD, MPH
Health Officer

Jennifer Vines, MD, MPH
Deputy Health Officer

Clark County Public Health
Cowlitz County Health Department
Skamania County Health Department
Wahkiakum County Department of Health and Human Services

(360) 397-8412

Please Distribute

Categories of Health Alert messages:

Health Alert: conveys the highest level of importance; warrants immediate action or attention.

Health Advisory: provides important information for specific incident for situation; may not require immediate action.

Health Update: provides updated information regarding an incident or situation; no immediate action necessary.
This advisory is adopted from an advisory was issued yesterday, May 12, 2010 by the Centers for Disease Control and Prevention (CDC)

Potential for Q Fever Infection Among Travelers Returning from Iraq and the Netherlands

Summary
Increasing reports of Q fever among deployed U.S. military personnel due to endemic transmission in Iraq, as well as a large ongoing outbreak of Q fever in the Netherlands, may place travelers to these regions at risk for infection. Healthcare providers in the Region IV should consider Q fever in the differential diagnosis of persons with febrile illness, pneumonia or hepatitis who have recently been in Iraq or the Netherlands. Physicians are encouraged to submit samples for proper laboratory testing and contact the CDC for consultation if needed. Q fever cases in travelers should be promptly reported to the appropriate local health department in Region IV.

Background
Since Operation Iraqi Freedom commenced in 2003, over 200 cases of acute Q fever have been reported among U.S. military personnel deployed to Iraq. Since several of these cases were identified after returning to the U.S. or when they were no longer serving on active military duty, a heightened awareness for Q fever infection occurring in military personnel and civilian contractors is necessary to ensure prompt diagnosis and appropriate treatment. Q fever is endemic in the Middle East, and transmission may be influenced by hot, dusty conditions and livestock farming practices which may facilitate windborne spread.

In addition, a large number of Q fever cases have occurred in the Netherlands since 2007, with over 3,700 human cases reported through March 2010. Infected dairy goat farms are believed to be the source of the outbreak, and the majority of human cases have been reported in the southern region of the country. To date, no imported cases of Q fever have been reported among American travelers returning home from the Netherlands.

Because travelers to these countries may have a higher likelihood of exposure to Q fever, the CDC Rickettsial Zoonoses Branch advises that physicians evaluate travelers returning from Iraq (particularly military personnel and civilian contractors) and the Netherlands with febrile illness, pneumonia or hepatitis for potential Q fever infection. Probable and confirmed cases should be reported to the appropriate Region IV local health department.

Q Fever Illness
Q fever is a zoonotic disease with both acute and chronic phases caused by the pathogen Coxiella burnetii. The primary mode of transmission to humans is inhalation of aerosols or dust contaminated by infected animals, most commonly cattle, sheep or goats. Direct animal contact is not required for transmission to occur as the organism may be spread by dust or wind. Infections via ingestion of contaminated dairy products and human-to-human transmission via
sexual contact have rarely been reported. Q fever does occur in the United States, but fewer than 200 cases are reported annually.

Although asymptomatic infections may occur, an unexplained febrile illness, sometimes accompanied by pneumonia and/or hepatitis, is the most common clinical presentation. Illness onset typically occurs within 2–3 weeks after exposure. The mortality rate for acute Q fever is low (1–2%), and the majority of persons with mild illness recover spontaneously within a few weeks although antibiotic treatment will shorten the duration of illness and lessen the risk of complications. Chronic Q fever is uncommon (<1% of acutely infected patients) but may cause life-threatening heart valve disease (endocarditis). Patients with pre-existing heart valve disorders, pregnant women, and immunosuppressed persons are at increased risk for developing chronic Q fever. A Q fever vaccine is not commercially available in the United States and antibiotic prophylaxis is not recommended.

Recommendations
Q fever is a notifiable disease in Washington. Please report all suspect cases to the appropriate health department (Clark, Cowlitz, Skamania or Wahkiakum County) at the following numbers:

- Clark County Public Health: (360) 397-8182.
- Cowlitz County Health Department: (360) 414-5599
- Skamania County Community Health: (509) 427-3850
- Wahkiakum County Health and Human Services (360) 795-6207

Please include information related to the patient’s travel history. Physicians seeing a patient – particularly military personnel or a civilian contractor - who has an illness consistent with Q fever and who has traveled to Iraq or the Netherlands in the 30 days prior to illness onset should perform appropriate laboratory testing. Serologic testing should be requested for IgG and IgM antibodies against C. burnetii Phase I and II antigen using indirect immunofluorescence assay (IFA). PCR assays may be conducted on whole blood samples in the early stages of illness and prior to initiation of antibiotic therapy.

Serologic evidence of a fourfold rise in IgG Phase II antibody by indirect immunofluorescence assay (IFA) between paired sera taken 2-4 weeks apart is the gold standard for diagnosis of acute infection. A single high serum Phase II IgG titer by IFA (≥ 1:128) is considered evidence of probable infection. IgM testing alone should not be used for serodiagnosis as false positives may occur. Treatment should not be delayed while awaiting laboratory results. Doxycycline (100mg twice a day for 2-3 weeks) is the treatment of choice for acute Q fever.

Whenever possible, physicians should submit paired acute and convalescent serum samples to facilitate optimal diagnostic testing.

<table>
<thead>
<tr>
<th>Type of sample</th>
<th>Interval from onset of symptoms to specimen collection</th>
<th>Type of Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute – whole blood</td>
<td>1-7 days (prior to antibiotic therapy)</td>
<td>PCR</td>
</tr>
<tr>
<td>Acute – serum</td>
<td>1-7 days</td>
<td>IFA for Phase I and II IgG and IgM</td>
</tr>
<tr>
<td>Convalescent – serum</td>
<td>21-35 days</td>
<td>IFA for Phase I and II IgG and IgM</td>
</tr>
</tbody>
</table>

Confirmatory laboratory testing should be performed by a reference laboratory. The Washington PHL does not perform testing for Q fever but will forward specimens to the CDC. Clinical laboratories should call PHL prior to shipping specimens (206-418-5400) for shipping
instructions. Serum should be submitted with a completed PHL microbiology form (http://www.doh.wa.gov/EHSPHL/PHL/Forms/Microbiology.pdf).

More Information

- Additional information about Q fever is available at: http://www.bt.cdc.gov/agent/qfever/clinicians/index.asp
- Call CDC’s toll-free information line, 800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, which is available 24 hours a day, every day.
- Contact the Rickettsial Zoonoses Branch at CDC: (404) 639-1075.